/
Other
Trial
138
Pipeline Programs↗
108
Active Trials↗
130
Companies Involved↗
Trial is a highly competitive landscape with 138 programs across 130 companies. The most active players are Mario Negri Institute for Pharmacological Research, Otsuka, Biohaven Therapeutics Ltd.. 27 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical23
Phase 120
Phase 268
Phase 327
Approved
No programs
Analysis
Modality Breakdown
88%
Small molecule
114 of 129 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 129 classified programs, each share of the total. Modality classified for 100% of 138 pipeline programs.
Analysis
Trial Status
789
clinical trials
Completed509 · 65%
Unknown status71 · 9%
Terminated62 · 8%
Recruiting56 · 7%
Withdrawn34 · 4%
Active, not recruiting28 · 4%
Other29 · 4%
Clinical Trials
Trial Activity
789 trials
MIVetsCan: Cannabidiol (CBD)-Care Trial
Recruiting·—·Phase 2·NCT06213233·468 enrolled
SWIFT - SWIss Factor XIII Trial in PPH
Recruiting·—·Phase 4·NCT06481995·988 enrolled
Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE)
Recruiting·—·Phase 2/3·NCT05766124·30 enrolled
Page 1 of 53
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)